The synthesis of specific, new MMP12-inhibition targeted drugs to treat oral diseases, featuring fewer side effects than the currently available broad-spectrum MMP inhibitors, is paramount to offer therapeutic benefit without interfering with other MMPs that have an important role in preventing disease progression and resolving tissue destruction [105]. The gene discussed is MMP12; the disease is mouth disorder.